FDA Calls Novartis' Melanoma Combo Drug a Breakthrough Post author:Sam Post published:October 22, 2017 Post category:BioPharma The FDA based its decision on data from the COMBI-AD Phase III trial. Source: BioSpace You Might Also Like Superstar Investors Jump in on Celgene Spinout Celularity's $250M Funding Round February 15, 2018 This Bay Area Biotech is Being Wooed by Drug Giant Novo Nordisk A/S March 8, 2017 3 Biotechs Seeking $271M IPO in the New Year January 1, 2018
